WO1993004701A1 - Targeted delivery of poly- or oligonucleotides to cells - Google Patents
Targeted delivery of poly- or oligonucleotides to cells Download PDFInfo
- Publication number
- WO1993004701A1 WO1993004701A1 PCT/US1992/007339 US9207339W WO9304701A1 WO 1993004701 A1 WO1993004701 A1 WO 1993004701A1 US 9207339 W US9207339 W US 9207339W WO 9304701 A1 WO9304701 A1 WO 9304701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- molecular complex
- oligonucleotide
- antisense
- binding agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940700741A KR100252547B1 (en) | 1991-09-05 | 1992-09-04 | Targeted delivery of poly- or oligonucleotides to cells |
JP5505335A JPH07500820A (en) | 1991-09-05 | 1992-09-04 | Targeted delivery of polynucleotides or oligonucleotides to cells |
AU26780/92A AU681997B2 (en) | 1991-09-05 | 1992-09-04 | Targeted delivery of poly- or oligonucleotides to cells |
EP92920863A EP0666923A1 (en) | 1991-09-05 | 1992-09-04 | Targeted delivery of poly- or oligonucleotides to cells |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75508391A | 1991-09-05 | 1991-09-05 | |
US07/755,083 | 1991-09-05 | ||
US78811991A | 1991-11-04 | 1991-11-04 | |
US07/788,119 | 1991-11-04 | ||
US86400392A | 1992-04-03 | 1992-04-03 | |
US07/864,003 | 1992-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993004701A1 true WO1993004701A1 (en) | 1993-03-18 |
Family
ID=27419474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/007339 WO1993004701A1 (en) | 1991-09-05 | 1992-09-04 | Targeted delivery of poly- or oligonucleotides to cells |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0666923A1 (en) |
JP (1) | JPH07500820A (en) |
KR (1) | KR100252547B1 (en) |
AU (1) | AU681997B2 (en) |
CA (1) | CA2116107A1 (en) |
WO (1) | WO1993004701A1 (en) |
Cited By (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024640A2 (en) * | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
WO1994013325A2 (en) * | 1992-12-15 | 1994-06-23 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
WO1994023050A1 (en) * | 1993-04-05 | 1994-10-13 | University Of Connecticut | Targeted delivery of genes encoding antisense polyribonucleotides |
WO1994023751A1 (en) * | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells |
WO1995006129A2 (en) * | 1993-08-20 | 1995-03-02 | Therexsys Limited | Transfection process |
WO1995019433A2 (en) * | 1994-01-12 | 1995-07-20 | Targetech, Inc. | Anti-hepatitis b poly- and oligonucleotides |
WO1995022618A1 (en) * | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
EP0674705A1 (en) * | 1992-11-09 | 1995-10-04 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
EP0681482A1 (en) * | 1993-01-22 | 1995-11-15 | University Research Corporation | Localization of therapeutic agents |
WO1995031566A1 (en) * | 1994-05-13 | 1995-11-23 | Chiron Viagene, Inc. | Compositions and methods for targeting gene delivery vehicles |
FR2721612A1 (en) * | 1994-06-23 | 1995-12-29 | Idm | Novel oligoside derivatives, process for their preparation and their applications |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US5623049A (en) * | 1993-09-13 | 1997-04-22 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics |
EP0821001A1 (en) * | 1995-03-31 | 1998-01-28 | Drug Delivery System Institute, Ltd. | Amidite derivatives and oligonucleotide derivatives |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5849893A (en) * | 1993-09-13 | 1998-12-15 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics |
WO1998056938A1 (en) * | 1997-06-13 | 1998-12-17 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
WO1999016883A2 (en) | 1997-10-01 | 1999-04-08 | Dana-Farber Cancer Institute | STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN |
US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
WO1999041273A2 (en) * | 1998-02-11 | 1999-08-19 | Perkin-Elmer Corporation | Pna and dna conjugates and methods for preparation thereof |
US5955571A (en) * | 1994-08-08 | 1999-09-21 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers for therapy and diagnosis |
US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO2000036131A1 (en) * | 1998-12-16 | 2000-06-22 | november Aktiengesellschaft Gesellschaft für Molekulare Medizin | Synthetic nucleic acid particle |
US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
EP1083232A1 (en) * | 1999-09-09 | 2001-03-14 | Jung, Günther, Prof. Dr. | Transfer of mRNA using polycationic compounds |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6271360B1 (en) | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
WO2001072765A1 (en) * | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
US6306993B1 (en) | 1997-05-21 | 2001-10-23 | The Board Of Trustees Of The Leland Stanford, Jr. University | Method and composition for enhancing transport across biological membranes |
WO2001089579A2 (en) * | 2000-05-19 | 2001-11-29 | Regents Of The University Of Minnesota | Composition for delivery of compounds to cells |
US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6335436B1 (en) | 1995-02-10 | 2002-01-01 | Hybridon, Inc. | Oligonucleotides active against drug-resistant bacteria |
WO2002079447A2 (en) | 2001-03-30 | 2002-10-10 | Avigenics, Inc. | Avian lysozyme promoter |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
US6593292B1 (en) | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
WO2004056308A2 (en) | 2002-11-26 | 2004-07-08 | Protein Design Labs, Inc. | CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
WO2005058937A2 (en) | 2003-12-12 | 2005-06-30 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
US6984729B1 (en) * | 1995-06-06 | 2006-01-10 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
WO2006043811A1 (en) * | 2004-10-21 | 2006-04-27 | Synvolux Ip B.V. | Vehicle for the transport of a chosen molecule to a cell |
WO2006081331A2 (en) | 2005-01-25 | 2006-08-03 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
US7148203B2 (en) | 1997-03-11 | 2006-12-12 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
WO2010128407A2 (en) | 2009-05-05 | 2010-11-11 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
WO2011091272A1 (en) | 2010-01-21 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
WO2011150079A1 (en) | 2010-05-25 | 2011-12-01 | Carnegie Mellon University | Targeted probes of cellular physiology |
US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
EP2629094A1 (en) | 2007-01-24 | 2013-08-21 | Carnegie Mellon University | Optical biosensors |
WO2013149111A2 (en) | 2012-03-29 | 2013-10-03 | Novimmune S.A. | Anti-tlr4 antibodies and uses thereof |
WO2013166500A1 (en) | 2012-05-04 | 2013-11-07 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
WO2014087248A2 (en) | 2012-12-03 | 2014-06-12 | Novimmune S.A. | Anti-cd47 antibodies and methods of use thereof |
US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
WO2015143194A2 (en) | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
WO2015164865A1 (en) | 2014-04-25 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
WO2015195917A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Monoclonal antibodies against her2 epitope and methods of use thereof |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
WO2016081423A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
EP3026432A2 (en) | 2010-12-27 | 2016-06-01 | Brown University | Method for predicting patient's response to biglycan treatment |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2017136676A1 (en) | 2016-02-05 | 2017-08-10 | Nanoview Diagnostics Inc. | Detection of exosomes having surface markers |
WO2017160754A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics,Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2018018039A2 (en) | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
WO2018048939A1 (en) | 2016-09-06 | 2018-03-15 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
EP3327039A1 (en) | 2010-06-02 | 2018-05-30 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
EP3333187A1 (en) | 2007-12-06 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
EP3511344A1 (en) | 2004-12-10 | 2019-07-17 | NovImmune S.A. | Neutralizing antibodies and methods of use thereof |
WO2019175658A1 (en) | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
-
1992
- 1992-09-04 WO PCT/US1992/007339 patent/WO1993004701A1/en not_active Application Discontinuation
- 1992-09-04 KR KR1019940700741A patent/KR100252547B1/en not_active IP Right Cessation
- 1992-09-04 EP EP92920863A patent/EP0666923A1/en not_active Ceased
- 1992-09-04 CA CA002116107A patent/CA2116107A1/en not_active Abandoned
- 1992-09-04 AU AU26780/92A patent/AU681997B2/en not_active Ceased
- 1992-09-04 JP JP5505335A patent/JPH07500820A/en active Pending
Non-Patent Citations (5)
Title |
---|
Journal of Biological Chemistry, Volume 264, No. 29, issued 15 October 1989, WU et al., "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo", pages 16985-16987, see entire article. * |
Proceedings of the National Academy of Sciences, Volume 77, No. 9, issued September 1980, HIRSCHMAN et al., "Expression of Cloned Hepatitis B Virus DNA in Human Cell Cultures", pages 5507-5511, see entire article. * |
Proceedings of the National Academy of Sciences, Volume 84, issued February 1987, LEMAITRE et al., "Specific Antiviral Activity of a Poly (L-Lysine)-Conjugated Oligodeoxyribonucleotide Sequence Complementary to Vesicular Stomatitis Virus N Protein mRNA Initiation Site", pages 648-652, see entire article. * |
Proceedings of the National Academy of Sciences, Volume 87, issued May 1990, WAGNER et al., "Transferrin-Polycation Conjugates as Carriers for DNA Uptake Into Cells", pages 3410-3414, see entire article. * |
See also references of EP0666923A4 * |
Cited By (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
US6022735A (en) * | 1991-09-30 | 2000-02-08 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
US6274322B1 (en) | 1991-09-30 | 2001-08-14 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
US6468798B1 (en) | 1991-12-17 | 2002-10-22 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol and liposome-based delivery |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
US5827703A (en) * | 1992-06-04 | 1998-10-27 | The Regents Of The University Of California | Methods and composition for in vivo gene therapy |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
WO1993025673A1 (en) * | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
WO1993024640A3 (en) * | 1992-06-04 | 1994-04-28 | Univ California | Methods and compositions for in vivo gene therapy |
WO1993024640A2 (en) * | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
US5968821A (en) * | 1992-10-16 | 1999-10-19 | Cold Spring Harbor Laboratories, Inc. | Cell-cycle regulatory proteins, and uses related thereto |
US6486131B2 (en) | 1992-10-16 | 2002-11-26 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US7425617B2 (en) | 1992-10-16 | 2008-09-16 | Cold Spring Harbor Laboratory | Antibodies to the cell cycle regulatory protein p16 |
EP0674705A4 (en) * | 1992-11-09 | 1997-11-26 | Univ Jefferson | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen. |
EP0674705A1 (en) * | 1992-11-09 | 1995-10-04 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
WO1994013325A2 (en) * | 1992-12-15 | 1994-06-23 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
WO1994013325A3 (en) * | 1992-12-15 | 1994-10-13 | Microprobe Corp | Peptide linkers for improved oligonucleotide delivery |
US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
EP0681482A4 (en) * | 1993-01-22 | 1998-07-01 | Univ Research Corp | Localization of therapeutic agents. |
EP0681482A1 (en) * | 1993-01-22 | 1995-11-15 | University Research Corporation | Localization of therapeutic agents |
WO1994023050A1 (en) * | 1993-04-05 | 1994-10-13 | University Of Connecticut | Targeted delivery of genes encoding antisense polyribonucleotides |
AU686614B2 (en) * | 1993-04-05 | 1998-02-12 | Targetech, Inc | Targeted delivery of genes encoding antisense polyribonucleotides |
WO1994023751A1 (en) * | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells |
WO1995006129A2 (en) * | 1993-08-20 | 1995-03-02 | Therexsys Limited | Transfection process |
WO1995006129A3 (en) * | 1993-08-20 | 1995-06-15 | Therexsys Ltd | Transfection process |
US5766902A (en) * | 1993-08-20 | 1998-06-16 | Therexsys Limited | Transfection process |
US5849893A (en) * | 1993-09-13 | 1998-12-15 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics |
US5623049A (en) * | 1993-09-13 | 1997-04-22 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics |
US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
WO1995019433A2 (en) * | 1994-01-12 | 1995-07-20 | Targetech, Inc. | Anti-hepatitis b poly- and oligonucleotides |
AU704562C (en) * | 1994-01-12 | 2007-08-23 | Targetech, Incorporated, A Wholly Owned Subsidiary Of The Immune Response Corporation | Anti-hepatitis B poly- and oligonucleotides |
AU704562B2 (en) * | 1994-01-12 | 1999-04-29 | Targetech, Incorporated, A Wholly Owned Subsidiary Of The Immune Response Corporation | Anti-hepatitis B poly- and oligonucleotides |
WO1995019433A3 (en) * | 1994-01-12 | 1995-10-19 | Targetech Inc | Anti-hepatitis b poly- and oligonucleotides |
US7186697B2 (en) | 1994-02-22 | 2007-03-06 | Dana-Farber Cancer Institute | Nucleic acid delivery system, methods of synthesis and use thereof |
WO1995022618A1 (en) * | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
WO1995031566A1 (en) * | 1994-05-13 | 1995-11-23 | Chiron Viagene, Inc. | Compositions and methods for targeting gene delivery vehicles |
WO1996000229A1 (en) * | 1994-06-23 | 1996-01-04 | I.D.M. Immuno-Designed Molecules | Novel oligosaccharide derivatives, preparation method therefor and uses thereof |
FR2721612A1 (en) * | 1994-06-23 | 1995-12-29 | Idm | Novel oligoside derivatives, process for their preparation and their applications |
US6251858B1 (en) | 1994-06-23 | 2001-06-26 | I.D.M. Immuno-Designed Molecules | Derivatives of oligosides, their process of preparation and their applications |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5955571A (en) * | 1994-08-08 | 1999-09-21 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers for therapy and diagnosis |
WO1996021036A3 (en) * | 1994-12-30 | 1996-09-06 | Viagene Inc | Nucleic acid condensing agents with reduced immunogenicity |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
US6335436B1 (en) | 1995-02-10 | 2002-01-01 | Hybridon, Inc. | Oligonucleotides active against drug-resistant bacteria |
EP0821001A1 (en) * | 1995-03-31 | 1998-01-28 | Drug Delivery System Institute, Ltd. | Amidite derivatives and oligonucleotide derivatives |
EP0821001A4 (en) * | 1995-03-31 | 2002-07-17 | Drug Delivery System Inst Ltd | Amidite derivatives and oligonucleotide derivatives |
US6984729B1 (en) * | 1995-06-06 | 2006-01-10 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
US7148203B2 (en) | 1997-03-11 | 2006-12-12 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
US6306993B1 (en) | 1997-05-21 | 2001-10-23 | The Board Of Trustees Of The Leland Stanford, Jr. University | Method and composition for enhancing transport across biological membranes |
US6495663B1 (en) | 1997-05-21 | 2002-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for enhancing transport across biological membranes |
US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
US6635623B1 (en) | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
WO1998056938A1 (en) * | 1997-06-13 | 1998-12-17 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
WO1999016883A2 (en) | 1997-10-01 | 1999-04-08 | Dana-Farber Cancer Institute | STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN |
US6197513B1 (en) | 1998-02-11 | 2001-03-06 | Pe Corporation | PNA and DNA conjugates and methods for preparation thereof |
WO1999041273A2 (en) * | 1998-02-11 | 1999-08-19 | Perkin-Elmer Corporation | Pna and dna conjugates and methods for preparation thereof |
WO1999041273A3 (en) * | 1998-02-11 | 1999-09-23 | Perkin Elmer Corp | Pna and dna conjugates and methods for preparation thereof |
US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
DE19858005B4 (en) * | 1998-12-16 | 2007-02-08 | november Aktiengesellschaft, Gesellschaft für Molekulare Medizin | Synthetic nucleic acid particle |
WO2000036131A1 (en) * | 1998-12-16 | 2000-06-22 | november Aktiengesellschaft Gesellschaft für Molekulare Medizin | Synthetic nucleic acid particle |
US8729010B2 (en) | 1999-08-24 | 2014-05-20 | Kai Pharmaceuticals, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6759387B2 (en) | 1999-08-24 | 2004-07-06 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US8623833B2 (en) | 1999-08-24 | 2014-01-07 | Kai Pharmaceuticals, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US8278264B2 (en) | 1999-08-24 | 2012-10-02 | Kai Pharmaceuticals, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6593292B1 (en) | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7060500B2 (en) | 1999-08-27 | 2006-06-13 | Metz Richard A | Single-stranded oligodeoxynucleotide mutational vectors |
US6479292B1 (en) | 1999-08-27 | 2002-11-12 | Valigen (Us), Inc. | Genetic alteration in plants using single-stranded oligodeoxynucleotide vectors |
EP2324856A1 (en) | 1999-08-27 | 2011-05-25 | Valigen (US), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
EP2266627A1 (en) | 1999-08-27 | 2010-12-29 | Valigen (US), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
US6271360B1 (en) | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
EP1083232A1 (en) * | 1999-09-09 | 2001-03-14 | Jung, Günther, Prof. Dr. | Transfer of mRNA using polycationic compounds |
WO2001072765A1 (en) * | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
WO2001089579A2 (en) * | 2000-05-19 | 2001-11-29 | Regents Of The University Of Minnesota | Composition for delivery of compounds to cells |
WO2001089579A3 (en) * | 2000-05-19 | 2002-08-29 | Univ Minnesota | Composition for delivery of compounds to cells |
US7199279B2 (en) | 2001-03-30 | 2007-04-03 | Avigenics, Inc. | Recombinant promoters in avian cells |
WO2002079447A2 (en) | 2001-03-30 | 2002-10-10 | Avigenics, Inc. | Avian lysozyme promoter |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US7375258B2 (en) | 2001-11-30 | 2008-05-20 | Avigenics, Inc. | Transgenic avians with an ovomucoid gene expression control region linked to a nucleotide sequence encoding a heterologous polypeptide |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
US7812215B2 (en) | 2001-11-30 | 2010-10-12 | Synageva Biopharma Corp. | Methods and protein production using ovomucoid promoters |
US7507873B2 (en) | 2001-11-30 | 2009-03-24 | Avigenics, Inc. | Transgenic avians containing recombinant ovomucoid promoters |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
WO2004056308A2 (en) | 2002-11-26 | 2004-07-08 | Protein Design Labs, Inc. | CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS |
EP2351583A1 (en) | 2002-11-26 | 2011-08-03 | Facet Biotech Corporation | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
WO2005058937A2 (en) | 2003-12-12 | 2005-06-30 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
WO2006043811A1 (en) * | 2004-10-21 | 2006-04-27 | Synvolux Ip B.V. | Vehicle for the transport of a chosen molecule to a cell |
EP3511344A1 (en) | 2004-12-10 | 2019-07-17 | NovImmune S.A. | Neutralizing antibodies and methods of use thereof |
WO2006081331A2 (en) | 2005-01-25 | 2006-08-03 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
US9856453B2 (en) | 2006-03-17 | 2018-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
US10214726B2 (en) | 2006-03-17 | 2019-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
US10557118B2 (en) | 2006-03-17 | 2020-02-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
EP2629094A1 (en) | 2007-01-24 | 2013-08-21 | Carnegie Mellon University | Optical biosensors |
EP3333187A1 (en) | 2007-12-06 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
US9249306B2 (en) | 2009-02-18 | 2016-02-02 | Carnegie Mellon University | Quenched dendrimeric dyes for florescence detection |
WO2010128407A2 (en) | 2009-05-05 | 2010-11-11 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP4089169A1 (en) | 2009-10-12 | 2022-11-16 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2011091272A1 (en) | 2010-01-21 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
WO2011150079A1 (en) | 2010-05-25 | 2011-12-01 | Carnegie Mellon University | Targeted probes of cellular physiology |
US9995679B2 (en) | 2010-05-25 | 2018-06-12 | Carnegie Mellon University | Targeted probes of cellular physiology |
EP3327039A1 (en) | 2010-06-02 | 2018-05-30 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
EP3026432A2 (en) | 2010-12-27 | 2016-06-01 | Brown University | Method for predicting patient's response to biglycan treatment |
WO2013149111A2 (en) | 2012-03-29 | 2013-10-03 | Novimmune S.A. | Anti-tlr4 antibodies and uses thereof |
WO2013166500A1 (en) | 2012-05-04 | 2013-11-07 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
EP3511343A1 (en) | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
WO2014087248A2 (en) | 2012-12-03 | 2014-06-12 | Novimmune S.A. | Anti-cd47 antibodies and methods of use thereof |
WO2015143194A2 (en) | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
WO2015164865A1 (en) | 2014-04-25 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
WO2015195917A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Monoclonal antibodies against her2 epitope and methods of use thereof |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
EP3699196A1 (en) | 2014-10-06 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
US10946098B2 (en) | 2014-11-17 | 2021-03-16 | Carnegie Mellon University | Activatable two-component photosensitizers |
WO2016081423A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
WO2017136676A1 (en) | 2016-02-05 | 2017-08-10 | Nanoview Diagnostics Inc. | Detection of exosomes having surface markers |
WO2017160754A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics,Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
WO2018018039A2 (en) | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018048939A1 (en) | 2016-09-06 | 2018-03-15 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
WO2019175658A1 (en) | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH07500820A (en) | 1995-01-26 |
KR100252547B1 (en) | 2000-09-01 |
AU2678092A (en) | 1993-04-05 |
AU681997B2 (en) | 1997-09-18 |
EP0666923A4 (en) | 1995-01-20 |
EP0666923A1 (en) | 1995-08-16 |
CA2116107A1 (en) | 1993-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6030954A (en) | Targeted delivery of poly- or oligonucleotides to cells | |
AU681997B2 (en) | Targeted delivery of poly- or oligonucleotides to cells | |
EP0894129B1 (en) | Short external guide sequences | |
Wu et al. | Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. | |
CA2210353C (en) | Stabilized external guide sequences | |
Kumasaka et al. | Role of the intercellular adhesion molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. | |
AU704562C (en) | Anti-hepatitis B poly- and oligonucleotides | |
AU2006261732B2 (en) | RNAi modulation of HIF-1 and theraputic uses thereof | |
CN107849567A (en) | A kind of siRNA, the pharmaceutical composition containing the siRNA and conjugate and their application | |
US5843770A (en) | Antisense constructs directed against viral post-transcriptional regulatory sequences | |
JP2018511307A (en) | Compounds and methods for modulating TMPRSS6 expression | |
CA2164288A1 (en) | Method for treating kaposi's sarcoma with antisense oligonucleotides | |
CA2205075C (en) | Reagent and method for inhibition of n-ras expression | |
CN103333890A (en) | RNA interference preparation used for treating viral hepatitis B | |
WO2003008628A2 (en) | Enzymatic nucleic acid peptide conjugates | |
US20020102694A1 (en) | Nucleozymes with endonuclease activity | |
AU686614B2 (en) | Targeted delivery of genes encoding antisense polyribonucleotides | |
EP4273245A1 (en) | Nucleic acid, pharmaceutical composition and sirna conjugate containing the nucleic acid, preparation method therefor, and use thereof | |
WO2023116607A1 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
CA2191192A1 (en) | Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure | |
JP3150609B2 (en) | Antisense oligonucleotides for cancer treatment | |
WO2005007854A2 (en) | Polycationic compositions for cellular delivery of polynucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2116107 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992920863 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1992920863 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1992920863 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992920863 Country of ref document: EP |